Aveo, BMS Team on Renal Cell Carcinoma Combo Therapy

Aveo Oncology has teamed up with Bristol Myers Squibb (BMS) to conduct a phase 3 trial evaluating its Fotivda (tivozanib) with BMS’ anti-PD-1 drug Opdivo (nivolumab) for renal cell carcinoma (RCC).

The trial is expected to enroll approximately 326 patients with advanced RCC who have progressed following immunotherapy treatment. The study will enroll participants at sites across the U.S., Europe and Latin America. Patients will be given either the Fotivda/Opdivo combination or Fotivda on its own.

Fotivda recently received FDA approval for treating adults with relapsed or refractory advanced RCC who have received two or more prior systemic therapies. BMS’ blockbuster Opdivo has been approved for multiple types of cancer, including nonsmall-cell lung cancer, melanoma, kidney cancer, bladder cancer and others.